Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drug

Bioconjugate Chemistry

Volumn 12, Issue 6, 2001, Pages 1074-1080

  Senter, P D ^a   Beam, K S ^a   Mixan, B ^a   Wahl, A F ^a  

^a SEATTLE GENETICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMICAL ACTIVATION; CYTOTOXICITY; DISEASES; DRUG DOSAGE; HYDROLYSIS;

ANTICANCER DRUG; CARBOXYLESTERASES; CYTOTOXIC ACTIVITIES; HUMAN ENZYMES; PRODRUG ACTIVATION; PRODRUGS; SIDE-CHAINS; SYSTEMIC TOXICITIES; THERAPEUTIC EFFICACY; TUMOR SITE;

ENZYME KINETICS;

ORYCTOLAGUS CUNICULUS;

EID: 0035213415     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc0155420     Document Type: Article

References (36)

1. Irintotecan in the treatment of colorectal cancer: Clinical overview
2. Irinotecan (CPT-11): Recent developments and future directions-colorectal cancer and beyond
3. Irinotecan CPT-11): Pharmacology and clinical applications
4. Clinical pharmacokinetics of camptothecin topoisomerase inhibitors
5. The clinical status ofirinotecan (CPT-11): A novel water soluble campothecin analogue: 1996
6. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse
7. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11
8. CPT-11 converting enzyme from rat serum: Purification and some properties
9. Metabolic activation of CPT-11, 7-ethyl-10[4-(1piperidino)-1-piperidino] carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase
10. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase
11. Expression and partial purification of a recombinant secretory form of human liver carboxyl-esterase
12. Proficient metabolism of irinotecan by a human intestinal carboxylesterase
13. Characterization of CPT-11 converting carboxylesterase activity in colon tumor and normal tissues: Comparison with p-nitrophenylacetate converting carboxylesterase activity
14. Human plasma carboxylesterase and butyrylcholinesterase enzyme activity: Correlations with SN-38 pharmakoinetics during a prolonged infusion of irinotecan
15. Gene-directed enzyme prodrug therapy
16. Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy
17. Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11
18. The anticancer prodrug CPT-11 in a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase
19. Reversal of CPT-11 resistance of lung cancer cells by adenovirus-mediated gene transfer of the human carboxylesterase cDNA
20. In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors
21. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2
22. Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs
23. Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates
24. Regressions and cures of melanoma xenografts following treatment with monoclonal antibody β-lactamase conjugates in combination with anticancer prodrugs
25. In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody β-lactamase conjugates
26. Characterization of molecular species of liver microsomal carboxylesterases of several animal species and humans
27. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines
28. Cytotoxicity of the antitumor agents cisplatin and taxol during cell proliferation and the cell cycle
29. Purification and cloning of a broad substrate specificity human liver carboxylesterase that catalyzes the hydrolysis of cocaine and heroin
30. The role of rat serum carboxylesterase in the activation of paclitaxel and camptothecin prodrugs
31. Prodrugs of doxorubicin and melphalan and their activation by a monoclonal antibody-penicillin-G amidase conjugate
32. First clinical experience with ADEPT
33. Intratumoral generation of 5-flourouracil mediated by an antibody-cytosine deaminase conjugate in combination with 5-fluorocytosine
34. Antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1: In vitro and in vivo studies with prodrugs of methotrexate and the thymidylate synthase inhibitors GW1031 and GW1843
35. Tumor-selective prodrug activation by fusion protein-mediated catalysis
36. Development and activities of a new melphalan prodrug designed for tumor-selective activation